{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antigen-Escalation+Stage",
    "query": {
      "intervention": "Antigen-Escalation Stage"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 238,
    "total_pages": 24,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antigen-Escalation+Stage&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-26T05:30:04.887Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04249947",
      "title": "P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostatic Neoplasms, Castration-Resistant",
        "Neoplasms by Histologic Type",
        "Neoplasms, Prostate",
        "Prostate Cancer",
        "Metastatic Castration-resistant Prostate Cancer",
        "Neoplasms",
        "Prostatic Neoplasms",
        "Genital Neoplasms, Male",
        "Urogenital Neoplasms",
        "Neoplasms by Site",
        "Prostatic Disease",
        "Salivary Gland Cancer",
        "Salivary Gland Tumor",
        "Adenoid Cystic Carcinoma",
        "Salivary Duct Carcinoma",
        "Mucoepidermoid Carcinoma",
        "Acinic Cell Tumor"
      ],
      "interventions": [
        {
          "name": "P-PSMA-101 CAR-T cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rimiducid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Poseida Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2020-02-28",
      "completion_date": "2024-09-30",
      "has_results": false,
      "last_update_posted_date": "2025-02-17",
      "last_synced_at": "2026-09-26T05:30:04.887Z",
      "location_count": 10,
      "location_summary": "Duarte, California • San Diego, California • San Francisco, California + 6 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04249947"
    },
    {
      "nct_id": "NCT02202447",
      "title": "Phase 1 of EC1169 In Patients With Recurrent MCRPC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "EC1169",
          "type": "DRUG"
        },
        {
          "name": "EC0652",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Endocyte",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 40,
      "start_date": "2014-05",
      "completion_date": "2018-11-29",
      "has_results": false,
      "last_update_posted_date": "2019-02-07",
      "last_synced_at": "2026-09-26T05:30:04.887Z",
      "location_count": 6,
      "location_summary": "Scottsdale, Arizona • New Haven, Connecticut • New Orleans, Louisiana + 3 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02202447"
    },
    {
      "nct_id": "NCT02050347",
      "title": "Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma",
        "B-Cell ALL",
        "B-Cell CLL"
      ],
      "interventions": [
        {
          "name": "CD19.CAR-CD28Z T Cells - dose escalation 2",
          "type": "GENETIC"
        },
        {
          "name": "CD19.CAR-CD28Z T Cells - dose escalation 1",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 7,
      "start_date": "2014-04",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2025-11-14",
      "last_synced_at": "2026-09-26T05:30:04.887Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02050347"
    },
    {
      "nct_id": "NCT01397227",
      "title": "A Study to Assess the Immunogenicity, Tolerability and Safety of a Malaria Vaccine and Also Its Protective Efficacy in a Malaria Challenge Model",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Malaria"
      ],
      "interventions": [
        {
          "name": "Ad35.CS.01/Ad26.CS.01 low dose (1 x 10^10 vp)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ad 35.CS.01/Ad 26.CS.01 high dose (5 x 10^10 vp)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Crucell Holland BV",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 36,
      "start_date": "2011-06",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2012-09-07",
      "last_synced_at": "2026-09-26T05:30:04.887Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01397227"
    },
    {
      "nct_id": "NCT07335328",
      "title": "Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "B-cell Non Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "1 X 10^6 cells/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "2.5 X 10^6 cells/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Dose expansion: The maximum tolerated dose of CAR-T cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 24,
      "start_date": "2026-09-01",
      "completion_date": "2031-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-11",
      "last_synced_at": "2026-09-26T05:30:04.887Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07335328"
    },
    {
      "nct_id": "NCT05366179",
      "title": "Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "CAR.B7-H3T cells infusion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2022-09-02",
      "completion_date": "2030-05-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-09-26T05:30:04.887Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05366179"
    },
    {
      "nct_id": "NCT06879041",
      "title": "A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Castration-Resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "AZD2287",
          "type": "DRUG"
        },
        {
          "name": "AZD2275",
          "type": "DRUG"
        },
        {
          "name": "AZD2284",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 136,
      "start_date": "2025-03-10",
      "completion_date": "2029-04-16",
      "has_results": false,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-09-26T05:30:04.887Z",
      "location_count": 12,
      "location_summary": "Palo Alto, California • San Diego, California • Miami, Florida + 9 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06879041"
    },
    {
      "nct_id": "NCT03648372",
      "title": "A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms",
        "Lymphoma",
        "Hematologic Neoplasms"
      ],
      "interventions": [
        {
          "name": "TAK-981",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 109,
      "start_date": "2018-10-01",
      "completion_date": "2023-12-14",
      "has_results": true,
      "last_update_posted_date": "2024-11-19",
      "last_synced_at": "2026-09-26T05:30:04.887Z",
      "location_count": 8,
      "location_summary": "La Jolla, California • Boston, Massachusetts • Detroit, Michigan + 5 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03648372"
    },
    {
      "nct_id": "NCT03820414",
      "title": "Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Herpes Zoster",
        "Varicella Zoster"
      ],
      "interventions": [
        {
          "name": "CRV 101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Curevo Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 90,
      "start_date": "2019-01-03",
      "completion_date": "2020-04-30",
      "has_results": false,
      "last_update_posted_date": "2021-02-11",
      "last_synced_at": "2026-09-26T05:30:04.887Z",
      "location_count": 1,
      "location_summary": "Kansas City, Missouri",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03820414"
    },
    {
      "nct_id": "NCT03635632",
      "title": "C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed Neuroblastoma",
        "Refractory Neuroblastoma",
        "Relapsed Osteosarcoma",
        "Relapsed Ewing Sarcoma",
        "Relapsed Rhabdomyosarcoma",
        "Uveal Melanoma",
        "Phyllodes Breast Tumor"
      ],
      "interventions": [
        {
          "name": "C7R-GD2.CART cells",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "1 Year to 74 Years"
      },
      "enrollment_count": 94,
      "start_date": "2019-04-23",
      "completion_date": "2038-05-16",
      "has_results": false,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-09-26T05:30:04.887Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03635632"
    }
  ]
}